PD-L1 IHC 28-8 pharmDx

DAKO (AGILENT) PD-L1 IHC 28-8 pharmDx in India

PD-L1 IHC 28-8 pharmDx
PD-L1 IHC 28-8 pharmDx Advancing Immunotherapy Options Cytotoxic T cells work to detect and eliminate infected cells and tumor cells from the body.
Read More
Add to Shortlist

Product Details

The pharmDx Solution is a portfolio of all-in-one pharmDx kits which give way to optimal diagnostic results within companion diagnostics. Correct results the first time supplement selecting the right therapy for each patient - each time. pharmDx encompasses personalized medicine pharmDx kits which make a difference to the assessment of suggestive patient treatment. The validated kits have the right specificity and sensitivity, while the correct results the first time deliver fewer reruns and help select the right therapy for each patient. This helps advance patient care by submitting fast results with great confidence and reduced time from biopsy to diagnosis.


 

PD-L1 IHC 28-8 pharmDx Advancing Immunotherapy Options Cytotoxic T cells work to identify as well as eliminate infected cells and tumor cells from the body. To lessen the damage to surrounding tissue, normal cells distinguish themselves by expressing a protein signal called PD-L1 (programmed death ligand 1). This PD-L1 signal is a stop sign developed to avoid elimination of normal cells by cytotoxic T cells. T cells detect the PD-L1 signal through a receptor called PD-1 (programmed death receptor 1). Some tumors can also deliver the PD-L1 signal to mimic normal cells and escape elimination. Anti-PD-1 therapy operates by blocking the PD-1/PD-L1 interaction. PD-L1 expression may be associated with patient benefit from anti-PD-1 therapy.

Read More